DexCom - DXCM Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

13 equities research analysts have issued twelve-month target prices for DexCom's shares. Their DXCM share price forecasts range from $103.00 to $145.00. On average, they expect the company's share price to reach $120.24 in the next year. This suggests a possible upside of 6.8% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

DexCom's stock was trading at $134.2375 at the beginning of the year. Since then, DXCM stock has decreased by 16.1% and is now trading at $112.62.
View the best growth stocks for 2022 here.

DexCom saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 12,590,000 shares, an increase of 5.8% from the October 31st total of 11,900,000 shares. Based on an average daily volume of 2,770,000 shares, the short-interest ratio is currently 4.5 days.
View DexCom's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our DXCM earnings forecast.

DexCom, Inc. (NASDAQ:DXCM) issued its earnings results on Thursday, October, 28th. The medical device company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.07. The medical device company had revenue of $650.20 million for the quarter, compared to analyst estimates of $617.07 million. DexCom had a net margin of 8.24% and a trailing twelve-month return on equity of 13.27%. The business's revenue was up 29.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.24 EPS.
Read the conference call transcript.

DexCom's stock split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were issued to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.88 billion-$2.91 billion, compared to the consensus revenue estimate of $2.89 billion.

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.31%), Baillie Gifford & Co. (4.61%), Sands Capital Management LLC (4.32%), Jennison Associates LLC (1.80%), Blair William & Co. IL (1.20%) and Price T Rowe Associates Inc. MD (1.03%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DXCM stock can currently be purchased for approximately $112.62.

DexCom (NASDAQ:DXCM) has a market capitalization of $43.50 billion and generates $2.45 billion in revenue each year. The medical device company earns $154.70 million in net income (profit) each year or $0.5425 on an earnings per share basis.

The company employs 7,000 workers across the globe.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.